clinical outcome of drug eluting stent for lmt · pdf filekawasaki social insurance hospital,...

31
Kawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu MD Kawasaki Social Insurance Hospital

Upload: vobao

Post on 24-Mar-2018

220 views

Category:

Documents


6 download

TRANSCRIPT

Page 1: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

Clinical Outcome of Drug Eluting Stent

for LMT Lesions

Toshiya Muramatsu MDKawasaki Social Insurance Hospital

Page 2: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

Classification of Bifurcartion Lesion

Type.1 Type.2 Type.3

Type.4 Type.4a Type.4b

-ICPS classification-

Page 3: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

Treatment for bifurcation lesions

VV--stentingstenting

TT--stentingstenting / / Modified TModified T--stentingstenting

““CulotteCulotte””oror YY stentinstentingg

Skirt Skirt stentingstentingCrushing /Crushing /ReverseReverse--CrushingCrushing

Kissing Kissing stentsstents

Page 4: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

0

25

50

75

Bare StentYamashitaBare StentYamashita

38.538.533.333.3

%%

6.06.0 6.26.2

CypherTM StentSIRIUS Bifurcations

CypherTM StentSIRIUS Bifurcations

Main Vessel In-Lesion Restenosis

Main Vessel Main Vessel InIn--Lesion Restenosis Lesion Restenosis

CypherTM Compared with Bare StentsCypherTM Compared with Bare Stents

From SIRIUS dataFrom SIRIUS data

Page 5: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

0

25

50

75

Bare StentYamashitaBare StentYamashita

%%

CypherTM StentSIRIUS Bifurcations

CypherTM StentSIRIUS Bifurcations

Side-Branch In-Lesion Restenosis

SideSide--Branch Branch InIn--Lesion RestenosisLesion Restenosis

CypherTM Compared with Bare StentsCypherTM Compared with Bare Stents

51.351.3

33.333.3

24.024.018.718.7

From SIRIUS dataFrom SIRIUS data

Page 6: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

472%5%07%

445%10%5%20%

Nmainsidebothrestenosis

Complex DES vs simple DES stentingComplex DES vs simple DES stenting

Pan M : Am Heart J 2004Pan M : Am Heart J 2004

Page 7: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

Crush Techniqueor

Y stenting

Page 8: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

IInstitut nstitut CCardiovasculaire ardiovasculaire PParis aris SSudud

Crush TechniqueCrush Technique

Derived from Sharma et al

Page 9: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

Benchtop testing

Ormiston 2003

2 layers3 layers

Problem of Crush!

Page 10: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

“Kissing” releases side-brfrom jail

After “crush”

Ormiston 2003

Page 11: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

Kissing Kissing No No Kissing Kissing p valuep valueAcute angiographic resultsAcute angiographic results

MB MB residual stenosis residual stenosis (%)(%) 22++44 99++1515 <0.05<0.05SB SB residualresidual stenosisstenosis (%)(%) 77++88 2020++1818 <0.0001 <0.0001

Crush Technique+ KBT

Moussa et al, ACC 2004

Role Role of Final of Final Kissing BalloonKissing Balloon InflationInflation

TVR (%)TVR (%) 1010 2222 NSNS

Page 12: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

Clulotte Stenting

••Full coverage of bifurcationFull coverage of bifurcation••No gap No gap

Pit holePit hole••2 times guide wire exchange2 times guide wire exchange••Sometimes, Balloon or Sometimes, Balloon or guidewireguidewire is difficult is difficult to cross beyond the to cross beyond the stentstent strut.strut.

••Chance to trapping guidewireChance to trapping guidewire••Small Stent CSA at intersection pointSmall Stent CSA at intersection point

Page 13: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

Y-stent (culotte stent) technique

LMT

LAD

LCxcross the guide wirestenting for LMT-LCxstenting for LMT-LADrecross the guide wirerecross the guide wirekissing balloon techniquefinal result

Page 14: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

Left Main TrunkDisease in DES

Page 15: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

Cypher stent for LMTN=78patients 78 lesions 2004.8~2005.11Age 70.7±10.0 y.o.Sex female 17

Diagnosis AMI 4caseUAP 12caseAP 62case

De novo lesion 63 lesionStent restenosis 15 lesion

Non protected LMT lesion 75lesion (96.1%)IABP support 4 case

Page 16: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

Lesion location

Ostium5 lesion6.4%

Shaft11 lesion14.1%

Bifurcation51 lesion65.4%

#6or 11just proximal11 lesion14.1%

Page 17: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

Strategy for LMT

Single stentLMT-LAD singleLMT-Cx singleγstentCutting stent

Two stentT-stentModified TCrush stentReverse CrushY-stentModified VSKS

De novon=63

ISR lesionn=15

29111

11212150

3101

1000900

Page 18: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

QCA results : LMT-LADAngiographical FU 58 cases (74.4%)

De novon=46

ISR lesionn=12

Pre MLDRef.d%DS

Post MLD

%DSFU MLD

Ref.d%DS

1.1±0.43.2±0.7

66.8±10.63.1±0.6

9.0±8.82.9±0.83.5±0.7

16.8±17.4

0.8±0.42.7±0.6

70.1±14.33.1±0.6

6.3±13.42.5±0.73.1±0.4

21.1±17.9

Page 19: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

QCA results : LMT-Cx

De novon=46

ISR lesionn=12

Post MLDRef.d%DS

FU MLDRef.d%DS

2.45±0.622.91±0.51

15.66±16.341.86±0.932.92±0.60

36.62±27.3

2.52±0.453.05±0.52

17.11±9.791.98±0.813.21±0.69

36.82±25.94

Page 20: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

Clinical results

Initial success 78(100%)In hospital MACE 0(0%)FU 213±97 days

Restenosis 11caseTVR 10case(17.2%)

Binary restenosis TVRLAD and Cx 2case 2case

LAD 0caseLCx 9case 8case

Page 21: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

TVR case

Both restenosis

Cx restenosis

2/0

8/0

Focal/DiffuseType of reste PreviousPCI LMT type

Ystent 2

Ystent 4Tstent 1Mod.V 3

Bif 2(100%)

Bif 8(100%)

Page 22: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

LMT

LAD

LCx

Pre-procedure

3.8 ± 1.5mm2

2.9 ± 1.5mm2

2.6 ± 1.7mm2

VA: 16.7 ± 7.0mm2

LA: 6.6 ± 3.7mm2VA: 21.3± 9.9mm2

LA: 7.9 ± 3.8mm2

VA: 11.9 ± 7.3mm2

LA: 6.3 ± 4.8mm2

Page 23: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

LMT

LAD

LCx

Post-procedure

4.7 ± 1.8mm2

4.1 ± 1.9mm2

8.8 ± 3.4mm2

5.0 ± 2.8mm2

5.3 ± 3.1mm2

73.6%

MSA/ref LA

89.9%

99.3%

102.2%

Page 24: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

LMT

LAD

LCx

Post-procedure

de novo: 4.5 ± 1.9mm2

Stent in stent: 5.0 ± 1.7mm2

de novo: 4.3 ± 1.8mm2

Stent in stent: 3.5 ± 1.8mm2

Page 25: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

Minimal stent CSA, ref. EEM CSA

0

5

10

15

20

25

de novo SIS Y-stent SIS+Y-stentn=17 n=6 n=11

7.2

16.7

n=49

6.8

4.8 3.9

15.915.8

20.6*

** ***

* p<0.05 vs de novo, Y-stent, SIS+Y-stent** p<0.05 vs de novo, SIS***p<0.0001 vs de novo, SIS

(mm2) minimal stent CSAref. EEMCSA

Page 26: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

Paclitaxel eluting stent for LMT bifurcation

NDeathDeath or MITVR

Repeat PCICABG

Death or MI or TVR

PES4901

01(2%)2(4%)

BMS5745

6(10.5%)9(15.7%)20(35%)

P value

<0.001<0.001

<0.001<0.001<0.001

Carrie D et al : Eur Interv 1. 396-402

Page 27: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

Paclitaxel eluting stent for LMT bifurcation

0

22.8

6.15.3

0

7 6.1

35.1

0

5

10

15

20

25

30

35

40

PB SB PB+SB all

PESBMS

<0.0001 <0.0001<0.001

-Angiographic Restenosis-

Carrie D et al : Eur Interv 1. 396-402

Page 28: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

13

28

23

35

0

5

10

15

20

25

30

35

3mon 6mon

LMCA-LADLCX

Sirolimus eluting stent for LMT bifurcation

Price MJ et al : JACC 47,871,06

Page 29: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

19

9.5

48

24

0

10

20

30

40

50

1 月

LMCALADostiumLCXostiumLAD,Cxos

Sirolimus eluting stent for LMT bifurcation

Price MJ et al : JACC 47,871,06

Page 30: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

Technical Point of DES for Bifurcation1.少なくとも本幹を確保する2.側枝のアクセスは概ね可能3.血菅径3.0mm以下や石灰化病変、屈曲性の場合、側枝のアクセス注意

3.Yステントか本幹のみのステントか?4.側枝へのガイドワイヤーはコーティングワイヤー、一体型ワイヤーが安全

5.Trapped wireの時には1.5mmのバルーンで隙間を拡張する(無理に引き抜くとちぎれるおそれあり)

1.Preserve for main vessel is important. 1.Preserve for main vessel is important. 2.Almost GW and Balloon can access the strut to side branch.2.Almost GW and Balloon can access the strut to side branch.3.However, it care about RD<3.0mm, calcium, 3.However, it care about RD<3.0mm, calcium, tortoustortous vessel.vessel.3.Safe use of coating wire cross to side branch. 3.Safe use of coating wire cross to side branch. 44.If Trapped wire occurred,1.5mm balloon .If Trapped wire occurred,1.5mm balloon dailatationdailatation is usefulis useful.55.Never strongly withdraw of trapped .Never strongly withdraw of trapped guidewireguidewire..66.Insufficient dilatation frequently occurred at intersection .Insufficient dilatation frequently occurred at intersection

point especially LMT to CX.point especially LMT to CX.77.Bifucation ISR lesion is highly .Bifucation ISR lesion is highly restenosisrestenosis cases.cases.88.Modified T.Modified T--stentingstenting will be hopeful??will be hopeful??

Page 31: Clinical Outcome of Drug Eluting Stent for LMT · PDF fileKawasaki Social Insurance Hospital, Kanagawa, Japan Clinical Outcome of Drug Eluting Stent for LMT Lesions Toshiya Muramatsu

Kawasaki Social Insurance Hospital, Kanagawa, Japan

Even DES Era

One stent better than two stentsfor Bifuraction